Asia Pacific Companion Animal Cardiac Drugs Market Size & Outlook
The companion animal cardiac drugs market in Asia Pacific is expected to reach a projected revenue of US$ 851.8 million by 2033. A compound annual growth rate of 10.52% is expected of Asia Pacific companion animal cardiac drugs market from 2026 to 2033.
- Animal Health
- Animal Pharmaceuticals & Biotechnology
- Companion Animal Cardiac Drugs Market Outlook
- Animal Pharmaceuticals & Biotechnology
Revenue, 2025 (US$M)
$392.7
Estimate, 2026 (US$M)
$422.8
Forecast, 2033 (US$M)
$851.8
CAGR, 2026 - 2033
10.5%
Global Market
Related Markets
Prism AI by Grand View ResearchFree to try
Ask a question about the companion animal cardiac drugs market
Every figure cited from GVR research
Asia Pacific companion animal cardiac drugs market highlights
- The Asia Pacific companion animal cardiac drugs market generated a revenue of USD 392.7 million in 2025.
- The market is expected to grow at a CAGR of 10.52% from 2026 to 2033.
- In terms of segment, dogs was the largest revenue generating animal type in 2025.
- Cats is the most lucrative animal type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 392.7 million |
| Market revenue in 2033 | USD 851.8 million |
| Growth rate | 10.52% (CAGR from 2026 to 2033) |
| Largest segment | Dogs |
| Fastest growing segment | Cats |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Dogs, Cats, Horses, Others Animal Type |
| Key market players worldwide | Boehringer Ingelheim, CEVA Inc, Elanco Animal Health Inc, Virbac SA, Zoetis Inc Class A, Dechra Pharmaceuticals, Bimeda, Biogenesis Bago, Merck KGaA, Vetoquinol SA |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 19.7% of the global companion animal cardiac drugs market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 851.8 million by 2033.
No credit card required*
Publish Date: Jul 22, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Companion Animal Cardiac Drugs Market Scope
Companion Animal Cardiac Drugs Market segmentation & scope
Companion Animal Cardiac Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Zoetis Inc Class A | View profile | 14,100 | 10 Sylvan Way, Parsippany, NJ, United States, 07054 | www.zoetis.com |
| Virbac SA | View profile | 5,400 | 2065m LID, 1 ere avenue, Carros, France, 06516 | www.virbac.com |
| CEVA Inc | View profile | 424 | 15245 Shady Grove Road, Suite 400, Rockville, MD, United States, 20850 | www.ceva-dsp.com |
| Elanco Animal Health Inc | View profile | 9,800 | 2500 Innovation Way, Greenfield, IN, United States, 46140 | www.elanco.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Vetoquinol SA | View profile | 2,483 | Magny-Vernois, BP 189, Lure cedex, France, 70204 | www.vetoquinol.com |
| Dechra Pharmaceuticals | View profile | 501-1000 | Northwich, Cheshire, United Kingdom, Europe | www.dechra.com |
| Biogenesis Bago | View profile | 501-1000 | Garín, Buenos Aires, Argentina, South America | www.biogenesisbago.com/en/ |
| Bimeda | View profile | 1001-5000 | Dublin, Dublin, Ireland, Europe | www.bimeda.com/ |
Asia Pacific Companion Animal Cardiac Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Companion Animal Cardiac Drugs Market Outlook will help companies and investors design strategic landscapes.
Dogs was the largest segment with a revenue share of 68.47% in 2025.
Horizon Databook has segmented the Asia Pacific companion animal cardiac drugs market based on dogs, cats, horses, others animal type covering the revenue growth of each sub-segment from 2021 to 2033.
- Asia Pacific Companion Animal Cardiac Drugs Market Animal Type Outlook (Revenue, USD Million , 2021-2033)
- Dogs
- Cats
- Horses
- Others Animal Type
- Asia Pacific Companion Animal Cardiac Drugs Market Product Outlook (Revenue, USD Million , 2021-2033)
- Pimobendan
- Spironolactone and Benazepril Hydrochloride
- Furosemide
- Others Product
- Asia Pacific Companion Animal Cardiac Drugs Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Congestive Heart Failure
- Myocardial (Heart Muscle) Disease
- Arrhythmias
- Others Indication
- Asia Pacific Companion Animal Cardiac Drugs Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Veterinary Hospitals & Clinics
- Others End Use
- Asia Pacific Companion Animal Cardiac Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital/ Clinic Pharmacy
- Retail
- E-Commerce
Reasons to subscribe to Companion Animal Cardiac Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Companion Animal Cardiac Drugs Market Outlook databook
- Our clientele includes a mix of Companion Animal Cardiac Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Companion Animal Cardiac Drugs Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Companion Animal Cardiac Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Companion Animal Cardiac Drugs Market, 2021-2033 (US$M)
Asia Pacific companion animal cardiac drugs market statistics, by animal type, 2021-2033 (US$M)
